Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Ítems similars

• Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
  per: Newsome, Scott D., et al.
  Publicat: (2016)
• Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
  per: Newsome, Scott D., et al.
  Publicat: (2018)
• Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
  per: Arnold, Douglas L, et al.
  Publicat: (2014)
• An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
  per: Bhargava, Pavan, et al.
  Publicat: (2016)
• Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
  per: Hendin, Barry, et al.
  Publicat: (2018)